Hausler R, Sabani E, Rohr M
Hôpital Cantonal Universitaire, Genève, Suisse.
Acta Otorhinolaryngol Belg. 1989;43(2):177-85.
The anti-vertigo effect of Cinnarizine (Stugeron R) has been tested in a controlled double blinded study on 40 patients suffering from various, well defined peripheral or central vestibular disorders. 12 patients out of 20 treated with 75 mg Cinnarizine twice a day during seven days demonstrated satisfactory vertigo suppression versus only 5 out of 20 treated with placebo. (
p less than 0.05). Particularly favorable results were obtained in patients suffering from sudden peripheral vestibular deficit, from vertigo of circulatory origin and from post traumatic vertigo. Results were less conclusive in patients with Menière's disease or central neurologic disorders (multiple sclerosis or heredito-degenerative diseases). The difference between the treated group and the placebo group was less striking after a prolonged treatment of eight weeks because of an important spontaneous improvement rate also in the placebo group. Electronystagmography did not show clearly detectable differences between patients treated with Cinnarizine and those treated with placebo. A temporary depressant effect on vestibular nystagmus was however electronystagmographically documented when the Cinnarizine dose was increased to 150 mg, (single dose) given to 5 healthy volunteers. The drug was generally well tolerated. Minor side effects were: slight somnolence (5 patients out of 19), slight headache (2/19) and transient abdominal pain (2/19).
已在一项针对40名患有各种明确的外周性或中枢性前庭疾病的患者进行的对照双盲研究中测试了桂利嗪（Stugeron R）的抗眩晕效果。在20名每天两次服用75毫克桂利嗪，持续七天的患者中，有12名眩晕得到了满意的抑制，而在20名服用安慰剂的患者中只有5名如此。（显著性：p小于0.05）。在患有突发性外周前庭功能缺损、循环源性眩晕和创伤后眩晕的患者中获得了特别良好的结果。在梅尼埃病或中枢神经系统疾病（多发性硬化症或遗传性退行性疾病）患者中，结果不太明确。由于安慰剂组也有较高的自发改善率，在进行了八周的长期治疗后，治疗组与安慰剂组之间的差异不那么明显。眼震电图检查未显示出服用桂利嗪的患者与服用安慰剂的患者之间有明显可检测到的差异。然而，当给5名健康志愿者单次服用150毫克桂利嗪时，眼震电图记录显示对前庭眼震有暂时的抑制作用。该药物一般耐受性良好。轻微的副作用有：轻度嗜睡（19名患者中有5名）、轻度头痛（2/19）和短暂性腹痛（2/19）。
